Home
Ask OE
ACE Reports
All Specialties All Specialties All Specialties Arthroplasty Arthroplasty Arthroplasty Foot & Ankle Foot & Ankle Foot & Ankle General Orthopaedics General Orthopaedics General Orthopaedics Hand & Wrist Hand & Wrist Hand & Wrist Metabolic Disorders Metabolic Disorders Metabolic Disorders Osteoarthritis Osteoarthritis Osteoarthritis Pediatric Orthopaedics Pediatric Orthopaedics Pediatric Orthopaedics Peri-Operative Peri-Operative Peri-Operative Physical Therapy & Rehab Physical Therapy & Rehab Physio & Rehab Shoulder & Elbow Shoulder & Elbow Shoulder & Elbow Spine Spine Spine Sports Medicine Sports Medicine Sports Medicine Trauma Trauma Trauma Tumour Tumour Tumour Author Interviews Author Interviews Author Interviews Conference Report Conference Report Conference Reports
Original Content
All Topics All Topics All Topics Education Education Education Innovation Innovation Innovation Leadership Leadership Leadership Other Other Other Personal Growth Personal Growth Personal Growth Practice Practice Practice Research Research Research
News
All News All News All News Innovation Innovation Innovation Other Other Other Research Research Research
Videos
All Videos All Videos All Videos Education Education Education Innovation Innovation Innovation Leadership Leadership Leadership Personal Growth Personal Growth Personal Growth Practice Practice Practice Research Research Research Webinars Webinars Webinars
About
Search
1 Avatar
Notifications
My Favorites
My Specialties & Interests
Newsletter Subscriptions
Unlock Notification.
To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trail account.
Basic Search
OR
Ask OE AI Search
Previous Ace Report AAOS2018: Additional compression pump to aspirin for thromboprophylaxis after TJA unnecessary Next Ace Report AAOS2018: Psoas compartment block versus PAI for postoperative analgesia in total hip arthroplasty
ACE Report Cover
Metabolic Disorders
AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
METABOLIC DISORDERS
AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women

Abaloparatide Reduced the Risk of Major Nonvertebral Fractures in Postmenopausal Women with Osteoporosis

Contributing Authors

PD Miller LA Fitzpatrick BH Mitlak G Williams MY Hu G Hattersley SV Bukata

1645 postmenopausal women with osteoporosis were randomized with daily subcutaneous injections or either abaloparatide 80ug or placebo for 18 months. Participants were followed up for the incidence of major non-vertebral fracture over 18 months of treatment. Results demonstrated a significantly lower incidence of major non-vertebral fracture among participants who received abaloparatide compared to participants who received placebo.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Start Free Trail
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with

OR
Forgot Password?
OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report
English (US) Portuguese French Spanish German Arabic

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women. ACE Report. 2018;7(3):34. Available from: https://myorthoevidence.com/AceReport/Show/aaos2018-abaloparatide-80ug-daily-reduces-rate-of-major-nvfs-in-osteoporotic-postmenopausal-women

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Upgrade to Premium!
Share this ACE Report